Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976417 | 1.00 | KISS1R (0.47) | KISS1RCPB2FOLH1EPHX1SIRT6 | |
| SCHEMBL14525109 | 1.00 | KISS1R (0.47) | KISS1RCPB2FOLH1EPHX1SIRT6 | |
| SCHEMBL23946773 | 0.98 | KISS1R (0.46) | KISS1RCPB2FOLH1EPHX1SIRT6 | |
| SCHEMBL12890790 | 0.94 | KISS1R (0.53) | KISS1RCPB2FOLH1EPHX1KDM4E | |
| SCHEMBL14525182 | 0.94 | KISS1R (0.53) | KISS1RCPB2FOLH1EPHX1KDM4E | |
| SCHEMBL13366903 | 0.94 | KISS1R (0.53) | KISS1RCPB2FOLH1EPHX1KDM4E | |
| SCHEMBL24155383 | 0.87 | KISS1R (0.45) | KISS1RCPB2FOLH1SIRT6SIRT1 | |
| SCHEMBL24155380 | 0.87 | KISS1R (0.45) | KISS1RCPB2FOLH1SIRT6SIRT1 | |
| SCHEMBL24155382 | 0.87 | KISS1R (0.45) | KISS1RCPB2FOLH1SIRT6SIRT1 | |
| SCHEMBL16221913 | 0.87 | KISS1R (0.45) | KISS1RCPB2FOLH1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238459-A1 | Granzyme-Activatable Membrane-Interacting Peptides and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-07-18 | — | — | US | disclosed |
| WO-2024036329-A2 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230330134-A1 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | STARPHARMA PTY LTD. (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20230330134-A1 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | STARPHARMA PTY LTD. (AU) | 2023-10-19 | — | — | US | disclosed |
| WO-2023163536-A1 | NOVEL ANTIBODY DRUG CONJUGATE | 앱티스 주식회사 | 2023-08-31 | — | — | WO | disclosed |
| US-11712483-B2 | Activatable membrane-interacting peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4212181-A2 | METHYLENE CARBAMATE LINKERS FOR USE WITH TARGETED-DRUG CONJUGATES | Seagen Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4190361-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| WO-2008071679-A9 | FIBRIN BINDING PEPTIDE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS. | BRACCO IMAGING SPA (IT) | 2009-01-15 | — | — | WO | disclosed |
| US-20080292675-A1 | Antimicrobial medicotechnical product, process for its production and use | AESCULAP AG (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080227696-A1 | Single branch heparin-binding growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071679-A1 | FIBRIN BINDING PEPTIDE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS. | BRACCO IMAGING SPA (IT) | 2008-06-19 | — | — | WO | disclosed |
| US-20080076816-A1 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | THE UNIVERSITY OF MANCHESTER (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080076816-A1 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | THE UNIVERSITY OF MANCHESTER (GB) | 2008-03-27 | — | — | US | disclosed |
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-20080008760-A1 | Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-01-10 | — | — | US | disclosed |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712483-B2 | Activatable membrane-interacting peptides and methods of use | ANXA5, PLA2G2A, F13B | KISS1R 2363/4885CPB2 95/4885FOLH1 663/4885 |
| US-20240238459-A1 | Granzyme-Activatable Membrane-Interacting Peptides and Methods of Use | GZMB, PRF1, PLA2G2A | KISS1R 3234/4885CPB2 172/4885FOLH1 1033/4885 |
| US-20080008760-A1 | Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry | CD47, CCR7, CCR6 | KISS1R 4807/4885CPB2 3165/4885FOLH1 941/4885 |
| US-20080076816-A1 | Nanotube complexes are water soluble, nontoxic; use in delivering biologicals such as DNA for gene therapy, DNA vaccines; amine salts derived from diethylenetriaminepentaacetic acid-modified nanotubes with anion such as DNA | DNTT, EEA1, DCTN1 | KISS1R 4866/4885CPB2 2561/4885FOLH1 996/4885 |
| US-20080227696-A1 | Single branch heparin-binding growth factor analogs | HDGF, HGF, FGF2 | KISS1R 326/4885CPB2 320/4885FOLH1 840/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | KISS1R 869/4885CPB2 1094/4885FOLH1 64/4885 |
| US-20230330134-A1 | METHOD OF PROPHYLAXIS OF CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION | SARS1, ACE, ACE2 | KISS1R 326/4885CPB2 323/4885FOLH1 1069/4885 |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | APP, APBA1, PSEN1 | KISS1R 1669/4885CPB2 1216/4885FOLH1 970/4885 |
| US-20080292675-A1 | Antimicrobial medicotechnical product, process for its production and use | ANPEP, HM13, PAM | KISS1R 3322/4885CPB2 1484/4885FOLH1 737/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | KISS1R 946/4885CPB2 2058/4885FOLH1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.